ArticleStatistics in medicine2021
Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies.
Article in Statistics in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- SurvGME: an R package for survival analysis with graphical and measurement error models.BMC bioinformatics · 2026Article
- Improving the efficiency of drug resistant tuberculosis treatment trials: a time-to-event alternative marker for bacteriological response and adaptive minimization for randomization.BMC medical research methodology · 2025Article
- Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysis.European journal of cancer (Oxford, England : 1990) · 2025Article
- A Multimodal MRI-Based Model for Colorectal Liver Metastasis Prediction: Integrating Radiomics, Deep Learning, and Clinical Features with SHAP Interpretation.Current oncology (Toronto, Ont.) · 2025Article
- Survival-inferred fragility of statistical significance in phase III oncology trials.NPJ precision oncology · 2025Article
- Non-collapsibility and built-in selection bias of period-specific and conventional hazard ratio in randomized controlled trials.BMC medical research methodology · 2024Article
- Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology.JCO precision oncology · 2024Article
- Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials.medRxiv : the preprint server for health sciences · 2024Article
- Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.JAMA cardiology · 2023Article
- Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes.NEJM evidence · 2022Article
- Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations.JNCI cancer spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.